Cre and LSL

I made these because I know I need help with understanding this topic

Explain the Lox-Stop-Lox (LSL) system in conditional gene expression. How does Cre recombinase interact with this construct, and what are the biological consequences of this interaction?

The LSL system contains a transcriptional stop codon flanked by loxP sites upstream of a target gene. Cre recombinase recognizes and excises the DNA between the loxP sites, removing the stop codon and allowing expression of the downstream gene. This enables spatiotemporal control of gene activation in specific tissues or developmental stages.

In the context of cancer biology, how is the LSL-Cre system used to model mutant p53 expression or Rb pathway disruption? Why is this advantageous over constitutive models?

The LSL system allows conditional activation of mutant alleles (e.g., p53^R172H) only after Cre expression, avoiding embryonic lethality or systemic effects. This enables tumor-specific modeling, such as expressing mutant p53 in the pancreas using Pdx1-Cre, creating more realistic and tractable cancer models.

Describe how tissue specificity is achieved using Cre recombinase in LSL systems. Give an example of a tissue-specific promoter used in mouse models and its relevance to tumor studies.

Tissue specificity is achieved by placing Cre under the control of a tissue-specific promoter (e.g., Pdx1 for pancreas, Nestin for neural tissue, MMTV for mammary glands). This ensures that recombination, and hence gene activation or deletion, occurs only in the desired tissue, allowing study of cancer development in its native cellular context.

What are the advantages and limitations of using LSL-Cre systems for modeling loss-of-function versus gain-of-function mutations in tumor suppressors like p53 or Rb?

Advantage: precise timing and tissue control.

Limitation: incomplete recombination, Cre toxicity, and potential leaky expression of the mutant allele even before Cre activation can confound interpretations.

How can LSL-Cre technology be used in combination with fluorescent reporters to trace lineage or monitor tumor progression in vivo?

A reporter gene (e.g., GFP, tdTomato) downstream of an LSL cassette allows visual confirmation of Cre activity. When combined with oncogene activation or tumor suppressor deletion, it permits lineage tracing, spatial mapping of recombination, and non-invasive tumor monitoring over time.

In a mouse model with an LSL-Kras^G12D and LSL-p53^R172H allele, how does co-expression of Cre drive tumorigenesis? What would be the effect of delivering Cre via an adenovirus to the lung epithelium?

Cre recombinase would simultaneously activate mutant Kras and mutant p53, promoting tumor initiation and progression. Adenoviral delivery to the lung localizes recombination to lung epithelial cells, generating a lung cancer model mimicking human non-small cell lung carcinoma.

What considerations should be made regarding Cre expression timing and dosage when interpreting phenotypes in LSL models, particularly for tumor suppressors like p53 or Rb?

Timing: Early Cre activation might affect development, while late activation might miss the tumor initiation window.

Dosage: High Cre expression can be toxic or cause off-target recombination. Ensuring efficient but specific Cre expression is key to accurately studying gene function in disease contexts.